In addition to its expected therapeutic effects, some adverse side effects may occur during treatment with ivosidenib. While not all side effects will···【Read More】
Update: 2026-03-09Source: Haiou HealthViews: 89
Enasidenib was developed by Celgene in the United States and approved for marketing by the US FDA on August 1, 2017.Enasidenib (EnglishIndications)Ena···【Read More】
Update: 2026-03-09Source: Haiou HealthViews: 94
Enasidenib is indicated for adult patients with relapsed or refractory acute myeloid leukemia (AML) who have been diagnosed with an isocitrate dehydro···【Read More】
Update: 2026-03-09Source: Haiou HealthViews: 94
Avatrombopag (Doptelet) increases platelet production by mimicking the action of endogenous thrombopoietin (TPO), activating TPO receptors, and promot···【Read More】
Update: 2026-03-09Source: Haiou HealthViews: 97
Avatrombopag (Doptelet) has different dosages and precautions for patients with chronic liver disease and chronic immune thrombocytopenic purpura. It ···【Read More】
Update: 2026-03-09Source: Haiou HealthViews: 93
Avatrombopag (Doptelet) is an oral small-molecule thrombopoietin receptor agonist (TPO-RA) that effectively increases preoperative platelet levels in ···【Read More】
Update: 2026-03-09Source: Haiou HealthViews: 93
When taking avatrombopag (Doptelet), serious side effects such as bleeding gums and nosebleeds, and abnormal weight gain or loss may occur; milder sid···【Read More】
Update: 2026-03-09Source: Haiou HealthViews: 92
On May 21, 2018, the U.S. Food and Drug Administration (FDA) approved avatrombopag (Doptelet) tablets for the treatment of thrombocytopenia (low plate···【Read More】
Update: 2026-03-09Source: Haiou HealthViews: 89
On June 27, 2019, the U.S. Food and Drug Administration (FDA) approved the expansion of the indication for avatrombopag (Doptelet) to include the trea···【Read More】
Update: 2026-03-09Source: Haiou HealthViews: 92
On July 25, 2025, the U.S. Food and Drug Administration (FDA) approved avatrombopag (Doptelet) for the treatment of thrombocytopenia in pediatric pati···【Read More】
Update: 2026-03-09Source: Haiou HealthViews: 96
Entrectinib is a targeted anticancer drug primarily used to treat solid tumors and lymphomas carrying specific gene mutations. Common side effects inc···【Read More】
Update: 2026-03-09Source: Haiou HealthViews: 93
Entrectinib is a targeted anticancer drug primarily used to treat solid tumors and lymphomas carrying specific gene mutations. Common side effects inc···【Read More】
Update: 2026-03-09Source: Haiou HealthViews: 93
The price of entrectinib fluctuates depending on the strength, purchase channel, and region. The original brand-name drug may be more expensive, while···【Read More】
Update: 2026-03-09Source: Haiou HealthViews: 98
The price of entrectinib varies depending on the region, health insurance policy, dosage, and purchase channel. The specific monthly treatment cost ne···【Read More】
Update: 2026-03-09Source: Haiou HealthViews: 90
IndicationsCrizotinib, also known as XALKORI, is indicated for the treatment of:ALK‑positive or ROS1‑positive metastatic non‑small cell lung cancer (N···【Read More】
Update: 2026-03-09Source: Haiou HealthViews: 89
Copyright2024@ BIGBEAR All right reserved Bigbear | Bigbear Pharmaceutical | Bigbear Laos



